Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Bodybuilding Health+ vs telos rx

Bodybuilding Health+
Graded #35

Lower grade

vs+9
telos rx
Graded #15

Higher grade

The verdict

telos rx takes it — 85/100 to 76/100.

telos rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A LegitScript-certified, HIPAA telehealth with one of the deepest published catalogs on the board — compounded semaglutide and tirzepatide (oral and microdosed routes included) alongside PT-141, intranasal NAD+, and a long recovery/GH peptide bench — with compounded GLP-1 starting from $49/mo on an annual plan.

Assume any provider we list may compensate us — we may earn a commission at no cost to you. It never changes the WeighScore.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueBodybuilding Health+ +1
88
87
Dose & formulationtelos rx +6
84
90
Clinical oversighttelos rx +10
74
84
Labs & monitoringtelos rx +12
68
80
Fulfillmenttelos rx +9
78
87
Contract termstelos rx +18
62
80
Bodybuilding Health+ · left bartelos rx · right bar

The numbers

MetricBodybuilding Health+telos rx
WeighScore76/10085/100
GradeCB
Scorecard rank#35#15
SemaglutideFrom $139/moFrom $49/mo (annual)
TirzepatideFrom $139/mo$99/mo (annual)
CoverageNot disclosedNot publicly listed
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
Bodybuilding Health+

Graded #35 · C

Strengths

  • Low, publicly listed bundle pricing — compounded semaglutide and tirzepatide both fall to $139/mo on the 12-month plan (first month $179 sema / $209 tirz)
  • Licensed brand extension of Bodybuilding.com (trademark relationship stated on-site), which lends familiarity vs. anonymous GLP-1 startups
  • Unusually broad menu under one login — GLP-1 plus NAD+ (injection or nasal), sermorelin (injection or sublingual ODT), ED/tadalafil, and a deep peptide catalog
  • Standard telehealth flow with clear FDA/compounding disclaimers — online intake reviewed by independent licensed providers, U.S. compounding-pharmacy fulfillment, free until a provider approves

Where it loses points

  • Compounded and not FDA-approved — not Wegovy/Ozempic or Zepbound/Mounjaro; the site itself states these have not been evaluated by the FDA for safety, effectiveness, or quality
  • Brand-new operator — Dynamo Group LLC launched the storefront around April 2026 with only a thin, mixed ~26-review Trustpilot record (cancellation and billing complaints)
  • All sales final — prescription products are non-returnable, the medical-consult fee is non-refundable, and there are no refunds for dissatisfaction or results
  • Pharmacy and provider network aren't named on the live consumer pages, no LegitScript seal we could verify on-site, and the catalog reaches into investigational Retatrutide and research-grade peptides
telos rx

Graded #15 · B

Strengths

  • Deep published catalog — sema, tirz, PT-141, intranasal NAD+, recovery/GH peptides, GHK-Cu, Dihexa, HRT
  • Needle-free and oral GLP-1 options, not injection-only
  • LegitScript-certified and HIPAA, with US providers and pharmacies, HSA/FSA and free shipping
  • Low GLP-1 entry — from $49/mo microdosed on an annual plan

Where it loses points

  • Everything is compounded and not FDA-approved, including the peptides
  • Pricing is opaque outside GLP-1 and the lowest rates require annual lock-in
  • No named clinicians and thin third-party reviews
  • Several research-grade peptides carry limited clinical evidence

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 35 providers, CoreAge Rx grades highest at 94/100 (A). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard